Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04309474




Registration number
NCT04309474
Ethics application status
Date submitted
13/03/2020
Date registered
16/03/2020
Date last updated
27/06/2023

Titles & IDs
Public title
A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke
Scientific title
A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke
Secondary ID [1] 0 0
2019-003753-29
Secondary ID [2] 0 0
M19-148
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Acute Ischemic Stroke 0 0
Condition category
Condition code
Stroke 0 0 0 0
Haemorrhagic
Stroke 0 0 0 0
Ischaemic
Neurological 0 0 0 0
Other neurological disorders
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Elezanumab
Treatment: Drugs - Placebo

Experimental: Elezanumab - Participants will receive elezanumab dose A

Placebo Comparator: Placebo - Participants will receive placebo for elezanumab


Treatment: Drugs: Elezanumab
Intravenous (IV) infusion

Treatment: Drugs: Placebo
Intravenous (IV) infusion
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
National Institutes of Health Stroke Scale (NIHSS) Total Score During the Treatment Period
Timepoint [1] 0 0
Week 0 through Week 52
Secondary outcome [1] 0 0
Responder Status based on Modified Rankin Scale (mRS)
Timepoint [1] 0 0
Week 0 through Week 52

Eligibility
Key inclusion criteria
- Clinical diagnosis of acute ischemic stroke, supported by acute brain computed
tomography (CT) or magnetic resonance imaging (MRI) consistent with the clinical
diagnosis.

- Able to randomize within 24 hours of last known normal.

- National Institute of Health Stroke Scale (NIHSS) total score of 7 to 21, inclusive.

- Participants or their legally authorized representative confirms that prior to index
stroke, no significant impairment in participant's ability to perform activities of
daily living without assistance.
Minimum age
30 Years
Maximum age
90 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Evidence of severe stroke on imaging based on available acute imaging studies
performed under the standard of care.

- Evidence of acute seizure at the onset of index stroke without conclusive imaging of
ischemic stroke.

- Evidence of acute myocardial infarction.

- Symptoms are considered likely to resolve within the subsequent few hours (e.g.,
transient ischemic attack [TIA]).

- Known history prior to randomization of clinically significant medical conditions
(other than current acute ischemic stroke) or any other reason, including any
physical, psychological, or psychiatric condition that in the investigator's opinion
would compromise the safety or interfere with the participant's participation in this
study.

- Known medical history of repeated episodes of complex migraine. Participants with
history of complex migraine, but with imaging conclusively demonstrating an acute
ischemic stroke are still allowed.

- Female who is pregnant, breastfeeding, or considering becoming pregnant during the
study or for within 39 weeks (5 half-lives) after the last dose of study drug.

- Known receipt of any investigational product within 30 days or 5 half-lives of the
drug (whichever is longer) prior to the first dose of study drug. No current
enrollment in another interventional clinical study, including pharmacologic and
behavioral interventional studies.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
9/11/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
23/02/2025
Actual
Sample size
Target
Accrual to date
Final
121
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Royal North Shore Hospital /ID# 239083 - St Leonards
Recruitment hospital [2] 0 0
The Royal Melbourne Hospital /ID# 240178 - Parkville
Recruitment postcode(s) [1] 0 0
2065 - St Leonards
Recruitment postcode(s) [2] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
District of Columbia
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Kentucky
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Mississippi
Country [9] 0 0
United States of America
State/province [9] 0 0
Missouri
Country [10] 0 0
United States of America
State/province [10] 0 0
New Jersey
Country [11] 0 0
United States of America
State/province [11] 0 0
New Mexico
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
Ohio
Country [14] 0 0
United States of America
State/province [14] 0 0
Pennsylvania
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
United States of America
State/province [16] 0 0
Virginia
Country [17] 0 0
Canada
State/province [17] 0 0
Alberta
Country [18] 0 0
Canada
State/province [18] 0 0
Ontario
Country [19] 0 0
Japan
State/province [19] 0 0
Fukuoka
Country [20] 0 0
Japan
State/province [20] 0 0
Kagoshima
Country [21] 0 0
Japan
State/province [21] 0 0
Nagano
Country [22] 0 0
Japan
State/province [22] 0 0
Yamaguchi
Country [23] 0 0
Korea, Republic of
State/province [23] 0 0
Gyeonggido
Country [24] 0 0
Korea, Republic of
State/province [24] 0 0
Busan
Country [25] 0 0
Korea, Republic of
State/province [25] 0 0
Seoul
Country [26] 0 0
Spain
State/province [26] 0 0
Guipuzcoa
Country [27] 0 0
Spain
State/province [27] 0 0
Vizcaya
Country [28] 0 0
Spain
State/province [28] 0 0
A Coruna
Country [29] 0 0
Spain
State/province [29] 0 0
Barcelona
Country [30] 0 0
Spain
State/province [30] 0 0
Madrid
Country [31] 0 0
Spain
State/province [31] 0 0
Sevilla

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AbbVie
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Stroke is one of the leading causes death and major functional disability worldwide.
Treatment options for acute stroke are limited with many patients having residual neurologic
impairment. The purpose of this study is to evaluate the safety and efficacy of elezanumab
and assess change in neurologic function in participants following an acute ischemic stroke.

Elezanumab is an investigational drug being developed for the treatment of acute ischemic
stroke. This 52-week study is "double-blinded', which means that neither the participants nor
the study doctors will know who will be given elezanumab and who will be given placebo (does
not contain treatment drug). Participants will be assigned to one of two groups, called
treatment arms. Participants in one arm will receive elezanumab and participants in the other
arm will receive placebo. There is a 1 in 2 chance that participants will be assigned to
placebo. Approximately 120 subjects will be enrolled in 45 sites worldwide.

Participants will be randomized to elezanumab or placebo by intravenous (IV) infusion within
24 hours of "last known normal" (time when the participant was last known to be without signs
and symptoms of the current stroke) and every 4 weeks thereafter for 48 weeks for a total of
13 doses.

There may be a higher treatment burden for participants in this trial compared to their
standard of care. Participants will attend regular visits during the course of the study at a
hospital or clinic. The effect of elezanumab will be checked by medical assessments, blood
tests, evaluation of side effects, and completion of questionnaires.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04309474
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
ABBVIE INC.
Address 0 0
AbbVie
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries